Benzyl 5-[3-(1,3-dioxoisoindolin-2-yloxy)propoxy]-3-chlorobenzoate | 245116-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: Benzyl 5-[3-(1,3-dioxoisoindolin-2-yloxy)propoxy]-3-chlorobenzoate
• 英文别名: benzyl 3-chloro-5-[3-(1,3-dioxoisoindol-2-yl)oxypropoxy]benzoate
• CAS: 245116-19-2
• 化学式: C₂₅H₂₀ClNO₆
• 分子量: 465.89
• InChiKey: ZUIFEYCGQBEBLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Benzyl 5-[3-(1,3-dioxoisoindolin-2-yloxy)propoxy]-3-chlorobenzoate 在 sodium hydroxide 、 甲胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-[3-[Bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]oxypropoxy]-5-chlorobenzoic acid
  参考文献：
  名称：

  Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis

  摘要：

  Through structure-based drug design and parallel synthesis, we have discovered a novel series of nonpeptidic phenyl-based thrombin inhibitors using oxyguanidines as guanidine bioisosteres. These compounds have been found to be highly potent, highly selective, and orally bioavailable. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.002
• 作为产物：
  描述：

  3,5-二氯苯酚 在 4-二甲氨基吡啶 、 草酰氯 、 四丁基氟化铵 、 caesium carbonate 、 magnesium 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 生成 Benzyl 5-[3-(1,3-dioxoisoindolin-2-yloxy)propoxy]-3-chlorobenzoate
  参考文献：
  名称：

  Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis

  摘要：

  Through structure-based drug design and parallel synthesis, we have discovered a novel series of nonpeptidic phenyl-based thrombin inhibitors using oxyguanidines as guanidine bioisosteres. These compounds have been found to be highly potent, highly selective, and orally bioavailable. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.002

文献信息

• Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors
  申请人：——

  公开号：US20010031870A1

  公开（公告）日：2001-10-18

  The present invention is directed to aminoguanidine and alkoxyguanidine compounds, including compounds of Formula I: 1 wherein X is O or NH, L is —O— or —SO 2 —, and R 1 -R 4 , R 9 -R 19 , R a , R b , R c , Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing the compounds of Formula I. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage.

  本发明涉及氨基胍和烷氧基胍化合物，包括公式I的化合物：其中X为O或NH，L为—O—或—SO2—，R1-R4，R9-R19，Ra，Rb，Rc，Y，Z，n和m在规范中设置，以及其水合物，溶剂化物或药学上可接受的盐，可抑制蛋白酶酶如凝血酶。还描述了制备公式I化合物的方法。其中某些化合物通过直接选择性抑制凝血酶表现出抗血栓活性，或是用于形成具有抗血栓活性的化合物的中间体。本发明包括一种用于抑制哺乳动物中的血小板丢失、抑制血小板聚集、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物。本发明化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于血液采集、血液循环和血液储存的设备制造材料中。
• Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals Inc.

  公开号：US06344466B2

  公开（公告）日：2002-02-05

  The present invention is directed to aminoguanidine and alkoxyguanidine compounds, including compounds of Formula I: wherein X is O or NH, L is —O— or —SO2—, and R1-R4, R9-R19, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing the compounds of Formula I. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage.

  本发明涉及氨基胍和烷氧基胍化合物，包括式I的化合物：其中X为O或NH，L为—O—或—SO2—，R1-R4，R9-R19，Ra，Rb，Rc，Y，Z，n和m在规范中列出，以及其水合物、溶剂化合物或药学上可接受的盐，可抑制蛋白酶酶如凝血酶。还描述了制备式I化合物的方法。其中某些化合物通过直接、选择性抑制凝血酶表现出抗血栓活性，或者是用于形成具有抗血栓活性的化合物的中间体。本发明包括一种组合物，用于抑制哺乳动物中的血小板丢失、抑制血小板聚集的形成、抑制纤维蛋白的形成、抑制血栓形成和抑制栓塞形成。本发明化合物的其他用途包括作为抗凝剂嵌入或物理连接到用于血液采集、血液循环和血液储存的器械制造材料中。
• US6274628
  申请人：——

  公开号：——

  公开（公告）日：——
• BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS
  申请人：3-DIMENSIONAL PHARMACEUTICALS, INC.

  公开号：EP1070049B1

  公开（公告）日：2004-06-30
• US6344466B2
  申请人：——

  公开号：US6344466B2

  公开（公告）日：2002-02-05